Skip to main content
. Author manuscript; available in PMC: 2012 Jun 14.
Published in final edited form as: Cancer Cell. 2011 Jun 14;19(6):715–727. doi: 10.1016/j.ccr.2011.04.016

Figure 3. p110γ PI3K activity is necessary and sufficient to promote myeloid cell trafficking to tumors.

Figure 3

Adhesion to VCAM-1 of chemoattractant-treated murine myeloid cells from (A) WT, p110γ−/− and p110γKD/KD mice (n=3), *p< 0.001 vs WT or (B) WT myeloid cells transfected with non-silencing, Pi3kα, β, γ, or δ siRNAs (n=3–6), *p< 0.001 vs non-silencing siRNA. (C) Adhesion to VCAM-1 of stimulated murine myeloid cells treated with TG100-115 and AS605240 (p110γ inhibitors), TGX221 (p110β inhibitor) or PI3Kα2 (p110α inhibitor). IC50TG100-115: IL-1β = 281 nM, SDF-1α = 158 nM; IC50AS605240: IL-β = 50 nM, SDF-1α = 50 nM. IC50 TGX221 and PI3Kα2 > 1 mM (n=3) *p<0.001 vs WT. (D) Adhesion to VCAM-1 of stimulated murine and human myeloid cells treated with TG100-115, AS605240, TGX221, or PI3Kα2. (E) VCAM-1/Fc binding to SDF-1α or IL-1β stimulated CD11b+ myeloid cells from WT or p110γ−/− mice or cells treated with 1 μM TG100-115, AS605240, PI3Kα2, TGX221 or control (n=3) *p<0.01 vs control. (F) Adhesion to VCAM-1 of unstimulated myeloid cells from WT and p110γCAAX mice (n=3), *p<0.01 vs WT. (G) Number/105 LLC tumor cells of adoptively transferred, fluorescently labeled myeloid cells transfected with non-silencing, Pi3k p110α, β, γ, or δ siRNAs, myeloid cells pretreated with TG100-115, PI3Kα2, or TGX221, and myeloid cells isolated from p110γ−/− mice (n=3), *p<0.001 vs non sil. siRNA. See also Figure S3.